Vitality Watch

Dossier pubmed preclinical 16-jun-2026
Animal model, organoid, or cell-culture result — not yet human

Resveratrol suppresses GATA4/Sortilin pathway to attenuate vascular smooth muscle cell senescence-associated secretory phenotype and vascular aging-related atherosclerosis.

Key claim: Resveratrol attenuates VSMC senescence, SASP, and atherosclerosis in ApoE mice by suppressing the GATA4/Sortilin pathway.

Abstract

This study aimed to investigate the role of Sortilin in vascular smooth muscle cell (VSMC) senescence and the senescence-associated secretory phenotype (SASP) and to explore whether GATA4 promotes VSMC senescence and aortic atherosclerosis by transcriptionally regulating Sortilin. Furthermore, we examined the potential of resveratrol (Res) to alleviate vascular aging and atherogenesis via the GATA4/Sortilin pathway. Bioinformatics analysis and experimental validation revealed co-upregulation of GATA4 and Sortilin in senescent VSMCs. Sortilin overexpression promoted VSMC senescence and SASP secretion, whereas its silencing resulted in the opposite effects. GATA4 transcriptionally activated Sortilin expression via direct binding to the Sort1 promoter, as confirmed by dual-luciferase reporter and chromatin immunoprecipitation (ChIP)-qPCR assays. Although GATA4-induced VSMC senescence was enhanced by co-overexpression of Sortilin, Sortilin knockdown did not significantly reverse GATA4-driven senescence, suggesting the involvement of additional mechanisms. Res treatment suppressed GATA4 and Sortilin expression, thereby attenuating VSMC senescence and the SASP. In apolipoprotein E-deficient (ApoE) mice fed a high-fat diet, AAV-mediated GATA4 overexpression promoted Sortilin expression, vascular oxidative stress, inflammation and accelerated aortic aging and atherosclerosis. These effects were counteracted by either AAV-Sortilin shRNA or dietary Res supplementation, which also improved blood lipid and glucose metabolism. In summary, GATA4 transcriptionally upregulates Sortilin expression, thereby promoting VSMC senescence and vascular aging. Res inhibits the GATA4/Sortilin pathway, suggesting a potential therapeutic strategy for ameliorating atherosclerosis.

Why this matters

Resveratrol’s cardiovascular story has long run ahead of its mechanisms; this ApoE-mouse work pins one slice of its anti-atherogenic effect to suppression of a GATA4→Sortilin axis driving VSMC senescence and SASP. It converges with other 2026 preclinical reports placing GATA4 upstream of tissue-local SASP (e.g., radiation-induced atrial fibrillation), suggesting GATA4 is becoming a recurring node in vascular-wall inflammaging regardless of trigger. Human translation remains unestablished — this is pathway detail in a mouse atherosclerosis model, not a clinical readout.

Source

Link

Briefing card

Resveratrol suppresses GATA4/Sortilin pathway to attenuate vascular smooth muscle cell senescence-associated secretory phenotype and vascular aging-related atherosclerosis.
Stage: preclinical · pubmed · 16-jun-2026

If you take resveratrol expecting cardiovascular-aging benefit, the supporting evidence here is still a mouse mechanism study, not a human outcome trial.

Resveratrol attenuates VSMC senescence, SASP, and atherosclerosis in ApoE mice by suppressing the GATA4/Sortilin pathway.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.cellsig.2026.112669

build build 880 · 2bcef25 · 2026-11-18